Drug Safety Strategies for Deprescribing Optimization in Complex Chronic Care

Abstract

Polypharmacy is prevalent in patients with complex chronic diseases, raising the risk of adverse drug events (ADEs), medication nonadherence, and therapeutic burden. Deprescribing is an evidence-based, patient-centered strategy for optimizing pharmacotherapy by systematically withdrawing or reducing unnecessary medications. This review synthesizes recent evidence and guideline recommendations on drug safety strategies for deprescribing in complex chronic care, addressing epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, management, advances, and practical implementation. The aim is to equip clinicians with actionable insights and mechanisms to enhance deprescribing safety, minimize harm, and optimize outcomes in multimorbid patients.

Introduction

Managing patients with multiple chronic conditions often necessitates complex medication regimens. However, the accumulation of prescriptions polypharmacy poses significant risks, including drug-drug interactions, adverse events, and decreased adherence. Deprescribing, defined as the planned and supervised process of dose reduction or stopping of medications that may no longer be beneficial or may be causing harm, is increasingly recognized as a core component of patient safety in chronic care. Recent clinical guidelines and research underscore the importance of structured deprescribing protocols, risk stratification, and shared decision-making to optimize therapeutic outcomes while minimizing iatrogenic complications. This article explores the scientific foundations, clinical implications, and emerging strategies for safe deprescribing in complex chronic care.

Epidemiology / Disease Burden

Polypharmacy affects up to 40% of older adults and is highly prevalent in those with multimorbidity. Studies indicate that 20-50% of these patients are prescribed at least one potentially inappropriate medication (PIM). The burden of ADEs attributed to polypharmacy is substantial, with an estimated 10% of hospitalizations in older adults linked to medication-related harm. The risk escalates in frail populations, those with cognitive impairment, and individuals transitioning between care settings. Epidemiological data from recent cohort studies and the World Health Organization highlight an urgent global need for systematic medication reconciliation and deprescribing interventions to mitigate avoidable harm.

Pathophysiology

The pathophysiology underlying medication-related harm in chronic care stems from altered pharmacokinetics and pharmacodynamics, age-related renal and hepatic impairment, and increased susceptibility to drug-drug and drug-disease interactions. Polypharmacy may exacerbate the "prescribing cascade," where side effects of one drug are treated with additional medications, compounding risk. Chronic comorbidities, such as chronic kidney disease, heart failure, and diabetes, further complicate metabolism and excretion, making the system more vulnerable to toxicity and suboptimal therapeutic response. Understanding these mechanisms supports rational deprescribing and risk stratification in clinical practice.

Risk Factors

Key risk factors for medication-related harm in the context of deprescribing include advanced age, cognitive dysfunction, frailty, multiple prescribers, recent hospitalization, and transitions of care. Polypharmacy itself, particularly involving central nervous system agents, anticholinergics, and drugs with narrow therapeutic indices, is a major risk factor. Pharmacogenomic variations and organ dysfunction especially hepatic and renal further modify individual drug safety profiles. Social determinants, such as limited health literacy and lack of care coordination, also elevate risk. Identification of these factors is essential for prioritizing patients who may benefit most from deprescribing interventions.

Clinical Features

Clinical features of medication-related harm are often nonspecific, including falls, delirium, confusion, gastrointestinal disturbances, and functional decline. These manifestations can mimic or exacerbate underlying chronic diseases, complicating diagnosis. In some cases, withdrawal syndromes or disease relapse may occur following abrupt cessation of certain medications, such as benzodiazepines or corticosteroids. Vigilant monitoring for both improvement in symptoms and emergence of withdrawal effects is critical during deprescribing, especially in the context of polypharmacy and multimorbidity.

Diagnosis

Diagnosing medication-related harm necessitates a thorough medication review, including prescription, over-the-counter, and herbal agents. Clinical decision support tools, such as the Beers Criteria and STOPP/START criteria, aid in identifying PIMs. Comprehensive geriatric assessment, medication reconciliation, and involvement of clinical pharmacists enhance diagnostic accuracy. Laboratory monitoring and assessment of drug levels may be indicated for medications with narrow therapeutic windows. Diagnostic algorithms that incorporate patient-specific factors and risk stratification tools further support safe deprescribing decisions.

Treatment & Management

Successful deprescribing involves a structured, individualized approach. Key steps include medication review, identification of medications for discontinuation based on risk-benefit analysis, shared decision-making with patients and caregivers, and development of a tapering plan when necessary. Close follow-up and monitoring for withdrawal or recurrence of symptoms are imperative. Interdisciplinary collaboration, particularly with pharmacists and geriatricians, improves safety and outcomes. Patient education regarding the rationale and expected outcomes of deprescribing fosters engagement and adherence. Barriers such as prescriber inertia, patient resistance, and fragmented care require targeted interventions, such as clinical pathways and decision aids.

Recent Advances / Emerging Therapies

Recent advances include the integration of electronic health records (EHR) with clinical decision support systems (CDSS) that flag PIMs and suggest deprescribing opportunities. Machine learning algorithms and risk prediction models are emerging tools for identifying high-risk patients and tailoring deprescribing interventions. Telemedicine and remote monitoring facilitate follow-up and early detection of adverse outcomes post-deprescribing. Research also supports the role of structured deprescribing protocols, such as the EMPOWER and TAPER studies, demonstrating improved safety and patient outcomes. Ongoing clinical trials are evaluating the long-term impact of deprescribing on morbidity, mortality, and quality of life in complex chronic care.

Guideline Recommendations

Contemporary guidelines from the American Geriatrics Society, NICE, and the Canadian Deprescribing Network emphasize a patient-centered, evidence-based approach to deprescribing. Recommendations include routine medication review in patients with multimorbidity, prioritization of high-risk medications for discontinuation, and use of validated tools for identifying PIMs. Guidelines advocate for interdisciplinary collaboration, shared decision-making, and consideration of patient goals and preferences. Tapering strategies, monitoring protocols, and patient education are integral components of safe deprescribing processes as outlined in these guidelines.

Conclusion

Optimizing drug safety in complex chronic care requires a proactive, systematic approach to deprescribing. Evidence-based strategies encompassing risk assessment, structured medication review, interdisciplinary collaboration, and patient engagement are essential for minimizing harm and enhancing therapeutic outcomes. Advances in clinical decision support and emerging research continue to refine best practices. Implementing guideline-based deprescribing strategies can substantially reduce the burden of polypharmacy and improve the quality of care for patients with chronic conditions.